期刊文献+

全自动血凝仪的性能评价及应用要求 被引量:2

Performance Evaluation of Automatic Coagulation Analyzer
下载PDF
导出
摘要 目的:通过德国BE血凝仪BECompact-X在临床实验室中的应用,对其性能进行评价。方法:建立标准曲线,用标准血浆分别建立德国BE血凝仪检测项目的标准曲线。进行精密度、准确性、污染率检测。结果:精密度试验批内cv值为1.15%~2.03%,批间cv值为1.27%~5.60%,符合质控要求;准确性在仪器允许范围内;污染率为0~1.2%,可见仪器在每次测定后经自动冲洗,自洁系统好。结论:实验表明德国BE血凝仪BECompact-X的各项技术指标符合要求,精密度高,准确度好,不但能满足目前临床止凝血指标检测的需求,而且对设定新的止血和血栓检测指标也具有较大潜能。 Objective:to evaluate the performance of Germany BE automatic coagulation analyzer BECompaet-X through its application in clinical laborary. Method:Drawing up standard curve of Germany BE coagulation analyzer examination items by using standard human plasma. Precision, accuracy and contamination rate were checked.Result: precision test intra cv value is between 1.21%-2.10%, inter ev value is between 1.24%-5.18%, which is in accordance with quality control requirement; accuracy is within the permissable range; contamination rate is between 0-1.2%. It is apparent that the instrument has good auto clean system. Conclusion:It is proven that Germany BE coagu- lation analyzer BECompact-X is qualified in all technical performance with high precision and accuracy, which can not only satisfy the demands of current clinical examination, but also show great potential for setting new blood arrest- ing and blood clots measurements.
作者 郭国明
出处 《安徽卫生职业技术学院学报》 2013年第2期101-102,共2页 Journal of Anhui Health Vocational & Technical College
关键词 全自动血凝仪 BECompact—X 检测 临床 automatic coagulation analyzer BECompact-X examination clinieal
  • 相关文献

参考文献7

二级参考文献49

  • 1韩雅玲,王祖禄.心房颤动患者血栓栓塞并发症的防治[J].中国实用内科杂志,2006,26(2):177-179. 被引量:34
  • 2孙艺红.华法林的临床应用与监测[J].中国实用内科杂志,2007,27(9):657-660. 被引量:26
  • 3[9]Poli D,Antonucei E,Cecchi E,et al.Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation:the role of homocysteine[J].Stroke,2005,36(10):2159-2163.
  • 4[10]Fang MC,Singer DE,Chang Y,et al.Gender differences in the risk of ischemie stroke and peripheral embolism inatrial fibrillation:the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study[J].Circulation,2005,112(12):1687-1691.
  • 5[11]Lip GY,Hart RG,Conway DS.Antithrombotic therapy for atrial fibrillation[J].BMJ,2002,325 (7371):1022-1025.
  • 6[12]Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC2006 guidelines for the management of patients with atrial fibrillation-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)[J].J Am Coil Cardiol,2006,48(4):854906.
  • 7[13]Go AS,Fang MC,Singer DE.Antithrombotic therapy for stroke prevention in atrial fibrillation[J].Prog Cardiovasc Dis,2005,48(2):108-124.
  • 8[14]Economides Munoz C,Singh BN.Antithrombotic therapies for stroke prevention in atrial fibrillation[J].Minerva Cardioangiol,2004,52 (2):125-139.
  • 9[15]O'Donnell M,Weitz JI.Emerging therapies for stroke prevention in atrial fibrillation[J].Eur Heart J,2005,7(Suppl C):C19-C27.
  • 10[16]Ostermayer SH,Reisman M,Kramer PH,et al.Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation:results from the international multi-center feasibility trials[J].J Am CoilCardiol,2005,46(1):9-14.

共引文献85

同被引文献12

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部